Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis

Alteration of specific cytokine expression patterns in patients with breast cancer

(2019) Kosuke Kawaguchi et al.   Scientific Reports

Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system

(2019) Amir Abbas Momtazi-Borojeni et al.   ATHEROSCLEROSIS

Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy

(2018) Parvin Zamani et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice

(2017) Christine Landlinger et al.   EUROPEAN HEART JOURNAL

P-407-induced Mouse Model of Dose-controlled Hyperlipidemia and Atherosclerosis

(2017) Thomas P. Johnston et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers

(2017) Alejandro Arrieta et al.   JAMA Cardiology

Liposomal Formulations in Clinical Use: An Updated Review

(2017) Upendra Bulbake et al.   Pharmaceutics

A Therapeutic Peptide Vaccine Against PCSK9

(2017) Yajie Pan et al.   Scientific Reports

Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9

(2016) Bryce Chackerian et al.   CURRENT OPINION IN LIPIDOLOGY

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

(2016) Brian A. Ference et al.   NEW ENGLAND JOURNAL OF MEDICINE

A cholesterol-lowering VLP vaccine that targets PCSK9

(2015) Erin Crossey et al.   VACCINE

New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory

(2015) Chris J. Packard et al.   VASCULAR PHARMACOLOGY

Cholesterol induces lipoprotein lipase expression in a tree shrew (Tupaia belangeri chinensis) model of non-alcoholic fatty liver disease

(2015) Linqiang Zhang et al.   Scientific Reports

Therapeutic Vaccines for Hypertension and Dyslipidemia

(2014) Hironori Nakagami et al.   International Heart Journal

Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management

(2014) Gergana Galabova et al.   PLoS One

New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?

(2013) Amirhossein Sahebkar et al.   CARDIOVASCULAR DRUGS AND THERAPY

Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis

(2013) Daniel Urban et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Active immunotherapy for chronic diseases

(2013) Martin F. Bachmann et al.   VACCINE

Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease

(2012) Brian A. Ference et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lipid Treatment Assessment Project 2

(2009) David D. Waters et al.   CIRCULATION

Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing

(2009) A. Schneeberger et al.   Journal of Nutrition Health & Aging